Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.19.1
Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Accrued expenses:    
Professional fees $ 1,434 $ 1,625
Salaries, bonuses and related benefits 5,843 5,279
Accrued expenses - related party 0 95
Research and development 3,805 1,873
Research and development - milestones 200 800
Research and development - manufacturing 826 1,188
Research and development - clinical supplies 160 85
Research and development - license maintenance fees 519 100
Dr. Falk Pharma settlement 300 3,059
Accrued royalties payable 1,108 1,411
Accrued coupon expense 838 1,087
Other 1,327 1,030
Total accrued expenses 16,360 17,632
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 5,211 4,739
Total other long-term liabilities $ 5,211 $ 4,739